Navigation Links
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007,AACR Annual Meeting

obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 27, 2006. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

    Contact:   Tapestry Pharmaceuticals, Inc.

               Gordon Link

               Senior Vice President, Chief Financial Officer

               303-516-8500

               


               Elma Hawkins, Ph.D.

               Communications and Corporate Development

               212-400-3019

               


    Investor:  Lilian Stern

               Stern Investor Relations, Inc.

               212-362-1200

               


    Media:     Lloyd Benson/Dana Conti

               Schwartz Communications

               781-684-0770

               

glink@tapestrypharma.com ehawkins@tapestrypharma.com lilian@sternir.com tapestry@schwartz-pr.com

CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,+1-303-516-8500, , or Elma Hawkins, Ph.D.,Communications and Corporate Development, +1-212-400-3019,, both of Tapestry Pharmaceuticals, Inc., orLilian Stern, Stern Investor Relations, Inc., +1-212-362-1200,, or Lloyd
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tapestry Pharmaceuticals Present Data TPI the AACR Annual Meeting
(Date:11/17/2014)... PARK, Calif. , Nov. 17, 2014 ... company in the emerging field of regenerative medicine, today ... President of Research and Development, will participate in a ... for Regenerative Medicine (CIRM) discussing the latest progress in ... The CIRM Google Hangout session is scheduled for ...
(Date:11/17/2014)... Wilson Therapeutics AB, a development stage biopharmaceutical company, ... study to evaluate efficacy and safety of its lead ... disorder and designated orphan disease, in which the body ... delighted to proceed with this important clinical study in ... development program for WTX101," said David Clark , ...
(Date:11/17/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ... their 2013 collaboration, option, and license agreement to co-develop ... as their research collaboration in prostate cancer. All of ... the product to other parties, will be returned to ... phase I clinical trial in the first half of ...
Breaking Medicine Technology:Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 2Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 4Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 5
... NEW YORK, June 2, 2011 Citeline, the world,s ... recently completed a comprehensive review of clinical trial starts ... patterns in drug development. Over the one-year review period ... trials were initiated in the oncology sector, more than ...
... Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today ... Trademark Office of Patent Application Serial No. 12/549458 ... This follows the UK issuance which was granted ... patent estate. The patent covers the ...
Cached Medicine Technology:Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 2Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 3Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 2Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 3
(Date:11/18/2014)... Cristcot Inc., a global life sciences ... specialized drug delivery systems, today announced that the ... for the technology, which encompasses the company’s commercially ... patent was awarded to the inventor Jennifer Davagian ... to Cristcot Inc. The patented technology, titled “Method ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... prove effective at lowering LDL ("bad") cholesterol levels for ... That,s the conclusion of a clinical trial presented ... Chicago. The drug, alirocumab, outperformed the on-the-market medication ... statins, Zetia, said lead researcher Dr. Patrick Moriarty, director ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Women who started smoking at ... chronic, severe menstrual pain, a new study suggests. ... While smoking has been suspected as a risk factor ... the authors of the new study said. The ... a long-term study of women,s health in Australia. About ...
(Date:11/18/2014)... 18, 2014 Global Partnership ... the telehealth platform to bring quality healthcare to ... passion, GPT created Global Partnership for TeleHealth Missions ... existing telehealth network. GPTM focuses specifically on ... and disaster relief organizations. , Michael ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... a History of Eating Disorders More at Risk for ... for Eating and Anxiety Disorders ( www.remudaranch.com ), the ... new pressure to look perfect while pregnant. "With the ... an increased pressure to look perfect and thin during ...
... is the only authorized online learning program ... Known for bringing innovation to the chiropractic ... only web-based seminar program dedicated exclusively to ... Online, the online learning system authorized by ...
... 19 Abbott announced today,that the U.S. ... the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for ... analyzer. , Cartridges for E3+, ... patient,s,metabolic state within a few minutes. The glucose ...
... Amazing Heat Pack by Comfort Now, Inc., a revolutionary ... pain relief for athletes, arthritics, chronic pain sufferers, premenstrual ... musclesBURLINGTON, Ontario, Jan. 19 Not since the 1920 ... aid product been released as The Amazing Heat Pack, ...
... Commitment to Healthy and Successful Vascular Access for ... Vascular Access(SM), the nation,s leading provider of vascular ... of managed vascular access centers has collectively ,touched, ... Lifeline Vascular Access managed center Nephrology Vascular Lab ...
... The 2008 Frost & Sullivan Technology Innovation Award ... presented to TECNIMED srl for pioneering THERMOFOCUS, the first ... available with a new, rapid, room temperature stabilization system. ... the company that has demonstrated technological superiority within its ...
Cached Medicine News:Health News:Remuda Ranch Reports More Women Seek to Be Thin During Pregnancy 2Health News:Activator Methods Introduces Web-Based Seminar Program 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3Health News:The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 2Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 4
... The Vitros 250 is ... meet requirements in multiple environments ... large hospitals, clinics and satellite ... features on-board dilution, and can ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: